pirfenidone extended release / Cipla - LARVOL DELTA

Following Computational Predictions, Scientists Demonstrate that Cancer Drug Counters Pulmonary Fibrosis (Yale School of Medicine) - "An experimental cancer drug with a favorable safety profile shows promise as a treatment for Idiopathic Pulmonary Fibrosis (IPF), according to a study published on August 23, 2022 in the American Journal of Respiratory and Critical Care Medicine by Yale School of Medicine, Mount Sinai, and National Jewish researchers....Lead researchers include...Maria L. Padilla, MD...Naftali Kaminski, MD..."

Media quote

Cipla Gets CDSCO Panel Nod for BE Study of Idiopathic Pulmonary Fibrosis Drug Pirfenidone (Medical Dialogues) - "Pharmaceutical major, Cipla has got a go-ahead from the Subject Expert Committee (SEC) of the Central Drug Standard Control Organization (CDSCO) to conduct the single dose and multiple dose Bioequivalence study (BE) of Pirfenidone Extended Release Tablets 1200 mg, which is a novel antifibrotic oral agent used for the treatment of idiopathic pulmonary fibrosis."

New trial • Idiopathic Pulmonary Fibrosis • Respiratory Diseases